Content area

Abstract

Objective:

Rheumatoid arthritis (RA) is a chronic autoimmune disease with limited treatment options and associated side effects or resistance. This study aims to investigate the therapeutic potential of the natural compound cucurbitacin B (CuB) in RA treatment.

Methods:

We utilized a collagen-induced arthritis (CIA) mouse model to evaluate the effects of CuB. Arthritis scores, histological damage, and pro-inflammatory cytokine expression (TNF-α, IL-17A) were assessed. In addition, network pharmacology analysis was performed to explore CuB’s molecular mechanisms, focusing on Th17 cell differentiation, IL-17 signaling, and the JAK-STAT pathway.

Results:

CuB significantly reduced arthritis severity, decreased histological damage, and lowered the expression of pro-inflammatory cytokines in CIA mice. CuB was found to inhibit STAT3 phosphorylation and reduce the proportion of Th17 cells in the spleen, indicating its potential anti-inflammatory effects.

Conclusion:

These findings suggest that cucurbitacin B may serve as a promising novel therapeutic agent for rheumatoid arthritis by targeting key inflammatory pathways.

Details

1009240
Company / organization
Title
Cucurbitacin B inhibits Th17 cell differentiation via the suppression of the JAK/STAT pathway and alleviates collagen-induced arthritis in mice
Author
Shu-Ping, Kung 1   VIAFID ORCID Logo  ; Hira, Umbreen 2 ; Wang Jou-Hsuan 3 ; Chih-Ming, Tsia 4 ; Lin Tim Chi-Chen 5 ; Yu-Ting, Chen 6   VIAFID ORCID Logo 

 Department of Pathology and Laboratory Medicine, Taichung Veterans General Hospital, Taiwan, China, R.O.C., Institute of Biomedical Science, National Chung Hsing University, Taichung, Taiwan, China, R.O.C. 
 Institute of Biomedical Science, National Chung Hsing University, Taichung, Taiwan, China, R.O.C. 
 Department of Physical Medicine and Rehabilitation, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan, China, R.O.C. 
 Division of Infectious Diseases, Department of Pediatrics, University of California, La Jolla, CA, USA, R.O.C. 
 Department of Pathology and Laboratory Medicine, Taichung Veterans General Hospital, Taiwan, China, R.O.C., Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, China, R.O.C., Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan, China, R.O.C., Department of Pharmacology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, China, R.O.C., The iEGG and Animal Biotechnology Center, National Chung Hsing University, Taichung, Taiwan, China, R.O.C. 
 Graduate Institute of Genomics and Bioinformatics, National Chung Hsing University, Taichung, Taiwan, China, R.O.C. 
Volume
39
Number of pages
18
Publication year
2025
Publication date
Jun 2025
Publisher
Sage Publications Ltd.
Place of publication
Chieti
Country of publication
United Kingdom
ISSN
03946320
e-ISSN
20587384
Source type
Scholarly Journal
Language of publication
English
Document type
Journal Article
Publication history
 
 
Online publication date
2025-06-01, 2025-06-01
Milestone dates
2024-11-21 (Received); 2025-05-25 (Accepted)
Publication history
 
 
   First posting date
01 Jun 2025
ProQuest document ID
3287004908
Document URL
https://www.proquest.com/scholarly-journals/cucurbitacin-b-inhibits-th17-cell-differentiation/docview/3287004908/se-2?accountid=208611
Copyright
© The Author(s) 2025 This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Last updated
2025-12-26
Database
ProQuest One Academic